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Background: We have initially published our experience with the robotic transthoracic esophagectomy in 32
patients from a single institute. The present paper is the extension of our experience with robotic system and to
best of our knowledge this represents the largest series of robotic transthoracic esophagectomy worldwide. The
objective of this study was to investigate the feasibility of the robotic transthoracic esophagectomy for esophageal
cancer in a series of patients from a single institute.
Methods: A retrospective review of medical records was conducted for 83 esophageal cancer patients who underwent
robotic esophagectomy at our institute from December 2009 to December 2012. All patients underwent a thorough
clinical examination and pre-operative investigations. All patients underwent robotic esophageal mobilization. En-bloc
dissection with lymphadenectomy was performed in all cases with preservation of Azygous vein. Relevant data were
gathered from medical records.
Results: The study population comprised of 50 men and 33 women with mean age of 59.18 years. The mean operative
time was 204.94 mins (range 180 to 300). The mean blood loss was 86.75 ml (range 50 to 200). The mean number of
lymph node yield was 18. 36 (range 13 to 24). None of the patient required conversion. The mean ICU stay and hospital
stay was 1 day (range 1 to 3) and 10.37 days (range 10 to 13), respectively. A total of 16 (19.28%) complication were
reported in these patents. Commonly reported complication included dysphagia, pleural effusion and anastomotic leak.
No treatment related mortality was observed. After a median follow-up period of 10 months, 66 patients (79.52%)
survived with disease free stage.
Conclusions: We found robot-assisted thoracoscopic esophagectomy feasible in cases of esophageal cancer. The
procedure allowed precise en-bloc dissection with lymphadenectomy in mediastinum with reduced operative
time, blood loss and complications.Background
The GLOBOCAN 2008 cancer fact sheet described
esophageal cancer as the eighth most common cancer
worldwide. There were 482,300 new cases of esophageal
cancer with 406,800 estimated deaths worldwide in year
2008 [1]. For esophageal cancer, esophagectomy remains
the cornerstone of the treatment with curative intent [2].
However, surgical resection of the esophageal cancer is a
challenging dissection compared to other gastrointes-
tinal cancers mainly due to anatomical difficulties. Add-
itionally, surgeries for esophageal cancer are frequently
associated with high rates of cardiopulmonary morbidity
and mortality [3,4]. Minimally invasive esophagectomy* Correspondence: shase63@gmail.com
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unless otherwise stated.(MIE) is being used increasingly with aim to reduce the
surgical trauma and thereby reducing morbidity and
mortality [4-6]. The available literature data shows other
advantages of MIE including decrease in operative time,
blood loss, post-operative complications and hospital
stay with comparable oncological clearance [4-6]. How-
ever, steep learning curve associated with MIE has been
a challenge [7,8].
Robotic surgery has generated considerable excitement
and interest in various oncological surgeries including
esophageal surgery. Robot-assisted surgery can acceler-
ate the learning curve of MIE with the help of magnified
three-dimensional view, improved articulation of instru-
ments with seven degree of freedom, improved dexterity
and enhanced ergonomics [8-11]. Robotic assisted sur-
gery can help the surgeon in precise dissection of the
structures in the mediastinum which otherwise wouldentral. This is an Open Access article distributed under the terms of the Creative
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in spite of various advantages of robotic esophagectomy,
it still remains in the early phase of acceptance.
We have initially published our experience with the
robotic transthoracic esophagectomy in 32 patients from
a single institute [11]. The present paper is the extension
of our experience with robotic system and to best of our




We retrospectively reviewed the medical records of 83
esophageal cancer patients who underwent robotic
assisted esophagectomy at Galaxy Care Laparoscopy
institute from December 2009 to December 2012. The
review was conducted on the basis of prospectively
recorded data from a computerized database. Care
Hospitals Institutional review board and ethics committee
approved the study. Each patient gave consent for con-
version to either thoracoscopic or open surgery just in
case of complications. Each patient’s consent was also
taken for use of video footage of their surgery for aca-
demic and research purposes (including specific written
consent from the patient whose edited operative video
is accompanying this manuscript). All patients under-
went a thorough clinical examination and pre-operative
investigations including routine hematogram, biochem-
ical investigations, pulmonary function tests, chest
radiograph, ECG, 2D Echo, contrast enhanced CT scan
of thorax and abdomen, upper GI endoscopy with bi-
opsy and barium swallow with stomach plates. Endo-
scopic ultrasound staging was done to identify the stage
of the tumor.
Patients with histologically proven squamous cell carcin-
oma, adenocarcinoma or dysplasia as well as other resect-
able forms of tumors were the candidate for the surgery.
The operability criteria were clearly defined as per NCCN
guidelines. American Society of Anesthesiologists (ASA)
class I to III was regarded appropriate for the procedure.
Patients with cervical esophageal cancer were not consid-
ered suitable for the procedure.
All the patients underwent robotic esophageal
mobilization. The entire thoracic esophagus along with
paraesophageal, subcarinal, paratracheal and bronchial
lymph nodes were removed en-bloc. Azygos vein was pre-
served in all cases. The resected specimen was examined
by an experienced pathologist. Pre-operative investigations,
clinical data, operative details, pathological details and
post-operative data were gathered from medical records.
Operative technique
The patient was placed in the prone position on an op-
erative sandbag. The robotic cart was situated to the leftside of the patient. The operative trocars for the robot
(one 12- mm port for the camera and two 8-mm ports
for the arms) were placed (Figure 1). The first port was
inserted 1 finger-breadth below and posterior to inferior
angle of scapula in the 5th or 6th intercostal space. Two
8-mm trocars were positioned under direct thoraco-
scopic vision in a vertical line at a distance of 5 cm and
in triangulation with the camera port in the third and
eighth intercostal spaces, respectively. One 10-mm port
for the assistant was placed between the left working
port and the camera port. This was used for suction and
clip application. Pneumoinsufflation was created at a
pressure of 7 mm Hg. (Additional file 1).
With the patient in a prone position, the esophagus
falls anteriorly out of its normal position, which creates
natural tension and simplifies dissection. We used
Maryland bipolar forceps in left arm and hot shears
(scissors with monopolar current) in right arm of the
robot. The procedure began with the incision of the vis-
ceral pleura between the esophagus and the lung just in-
ferior to the azygos vein. This helped in keeping the
esophagus attached to the pleura on the aortic side.
More than 3 fourths of the circumference of the esopha-
gus was mobilized in this way from the cranial to the
caudal direction. The plane of dissection was outside the
vagus. The posterior large direct aortic branches were
then clipped, and the small branches were cauterized
with bipolar forceps. This completed the mobilization of
the esophagus all around. The caudal limit of the dissec-
tion was the hiatus. The same dissection was continued
in the supra-azygos region. The vagal fibers going to the
bronchus were preserved. The azygos vein was pre-
served. Complete mobilization of the esophagus was
achieved. The specimen also included the lower and
middle mediastinal, subcarinal, and right paratracheal
nodes. The thoracic duct was identified and clipped in
all cases.
Stomach mobilization
Stomach mobilization was done laparoscopically. All the
nodes along the left gastric, paraesophageal, splenic and
along the hepatic artery were removed. The stomach
was mobilized on the right gastro epiploic and right
gastric artery. The stomach tube was prepared extracor-
porially by taking 5 cm incision in the midline.
Cervical incision
Left supraclavicular 3 cm incision was taken. The two
heads of the sternomastoid were separated and the
esophagus was pulled up to the wound. The esopha-
gus was cut and the NG tube was attached to the dis-
tal end. The specimen was removed abdominally. The
stomach tube was attached to the NG tube and was
pulled to the neck and hand sewn esophageogastric
Figure 1 Patient and port positioning.
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in all the patients.
Post-operative course
The patients were kept in ICU for minimum one day
after which shifted to respective ward. The continuous
monitoring of vital parameters was done further for next
48 hrs and then every day for the next 4 days. The chest
radiograph and hematogram was done every day for
2 days and then were repeated only when the patient
had respiratory signs, fever, or any other complaints.
Patients were made ambulatory after 24 hrs and jeju-
nostomy tube feeding was started after 48 hrs of surgery.
The leak test was performed on the 7th day of the sur-
gery and oral feeding was started accordingly.
The patients with nodal involvement were subjected to
chemotherapy or radiotherapy or both depending on
number of node positivity and histology of tumor. The
patients were followed 3 monthly for clinical checkup,
chest radiograph and ultrasonography for the period of
one year and than six monthly for a period of two years.
If any suspicion was raised PET scan was advised.
Results
The study population consisted of 83 patients, 50 men
(60.24%) and 33 women (39.76%). The mean age at sur-
gery was 59.18 years (range, 30 to 87 years). Most com-
monly involved site (50 cases, 60.24%) was lower third
of the esophagus. The predominant histology (67 cases,
80.72%) was squamous cell carcinoma. A total of 21.69% of
patients presented at least one comorbid condition, withhypertension and diabetes observed as most common
comorbidities. Information on patient demographics is
presented in Table 1.
The mean operative time was 204.94 minutes (range
180 to 300). The size of the tumor did not significantly
affect operative times. The mean blood loss was
86.75 ml (range 50 to 200). The mean number of lymph
node yield was 18. 36 (range 13 to 24). Only two patients
showed positive circumferential margin. None of the
patient required conversion to thoracoscopic or open
surgery. The mean ICU stay was 1 day (range 1 to 3)
and the mean hospital stay was 10.37 days (range 10
to 13). Table 2 represents operative and post-operative
outcomes.
Postoperative morbidity occurred in 16 cases (19.28%).
A total 19 of incidents were reported in these cases.
Dysphagia was the most commonly observed event
(6 cases, 7.23%) followed by pleural effusion (3 cases,
3.61%). Anastomotic leak was reported in 3 cases and
chyle leak was observed in one patient. There were only
two incidences of recurrent palsy. One patient developed
port site metastasis which was treated with excision. No
treatment related mortality was observed. At the end of
the study period, 66 patients (79.52%) were alive in disease
free stage at the median follow-up period of 10 months.
One patient was lost to follow up. Figure 2 shows the
Kaplan Meier survival analysis.
Discussion
To the best of our knowledge, this is the largest study
on robotic transthoracic esophagectomy till date which
Table 1 Clinico-demographic characteristics of the






21 – 30 1 (1.20)
31 – 40 5 (6.02)
41 – 50 15 (18.07)
51 – 60 22 (26.51)
61 – 70 28 (33.73)
71 – 80 9 (10.84)
81 – 90 3 (3.61)
Histology
Squamous cell carcinoma 67 (80.72)
Adenocarcinoma 12 (14.46)
Dysplasia 2 (2.41)
Gastrointestinal stromal tumor 1 (1.20)
Lymphoma 1 (1.20)
Site of cancer
Middle third 50 (60.24)
Lower third 20 (24.10)
Gastroesophageal junction 13 (15.66)
TNM stage of tumor










Diabetes mellitus 11 (13.25)
Bronchial asthma 3 (3.61)
Hypertension 15 (18.07)
Stroke 1 (1.20)
Ischemic heart disease 2 (2.41)
Hemiplagia 1 (1.20)
Table 2 Operative outcomes following the robotic
transthoracic esophagectomy
Variable Mean (range) or no. (%)
Total operative time (mins) 204.94 (180–300)
Docking time (mins) 9.06 (5–30)
Undocking time (mins) 5 (2–10)
Time for esophageal mobilization (mins) 104.08 (80–170)
Estimated blood loss (ml) 86.75 (50–200)
Lymphnode yield (no.) 18.36 (13–24)
ICU stay (days) 1 (1–3)
Hospital stay (days) 10.37 (10–13)
Nil by mouth (days) 9.40 (8–12)
Conversion (no.) Nil
Margin positivity (no.) 2 (2.41)
Adjuvant chemotherapy (no.) 15 (18.07)
Complications (no.)
Dysphagia for solids 6 (7.23)
Pleural effusion 3 (3.61)
Aspiration pneumonia 1 (1.20)
Recurrent palsy 2 (2.41)
Anastomotic leak 3 (3.61)
Chyle leak 1 (1.20)
Port site metastasis 1 (1.20)
Surgical site infection 1 (1.20)
Sepsis 1 (1.20)
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tute. As the available data in the literature on this ad-
vancement is scarce, we feel that the present study
perhaps will provide a better idea on the ‘real world’
scenario.Esophagectomy for esophageal carcinoma is a technic-
ally challenging procedure associated with relatively high
mortality and morbidity [7,12-14]. To reduce the
morbidity as a result of surgical trauma from open pro-
cedures, minimal invasive procedures were introduced
in the recent past. There are published reports that
favored the use of MIE due to advantages of shorter
operative time; reduced blood loss and shorter hospital
stay [7,12,15-17]. Nevertheless, the conventional MIE
methods are limited by the technical difficulties. Mainly,
the use of long instruments with limited degree of free-
dom and two-dimensional view can become hindrance
for optimal dissection [18,19].
The more recent introduction of robotic systems in
surgical oncology has answered the limitations of MIE.
Compared to the traditional minimally invasive proce-
dures, robotic-assisted surgery offers several potential
advantages. The improved visualization with the magni-
fied three-dimensional view is of particular benefit that
allows a precise and atraumatic dissection of the peri-
esophageal tissue along the vital structures, such as pul-
monary vein, trachea, thoracic duct, aorta and vagus
nerve [9,20]. More importantly, the magnified view of
Figure 2 Disease free survival following robotic transthoracic esophagectomy (Kaplan Meier Plot).
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tion of the lymph nodes. The lymphatic spread of
esophageal cancer is generally irregular due to submuco-
sal lymphatic drainage system. The radical resection of
esophagus with surrounding lymph nodes offers the best
possible cure. With the use of robotic arms, we were
able to achieve the mean lymph node yield of 18.36
(range 13 to 24). A study from van Hillegersberg R et al.
harvested a median of 20 lymph nodes (range, 9–30)
through robot-assisted thoracoscopic esophagectomy
[9]. Cerfolio et al. reported median number of 20
through the same approach [21]. Galvani et al. achieved
mean lymph nodes yield of 12 (range 7 to 27) using
robot-assisted transhiatal esophagectomy [22]. The same
approach was utilized by Dunn et al., who harvested a
median of 20 lymph nodes (range, 3–38) [23]. Sarkaria
et al. reported median number of 20 lymph nodes
(range, 10–49) using combined thoracoscopic and lap-
aroscopic robotic-assisted approach [24]. We believe
that the transthoracoscopic approach offers an outstand-
ing access to the mediastinum and thereby allows an
extended lymphadenectomy. When performing the pro-
cedure through the transhiatal approach, these potential
metastatic lymph nodes might be leftover in situ [25]. In
fact, the R0 resection was achieved in 97.59% of our
study population. Few other case series using the similar
approach showed R0 resection rate varying from 76% to
100% [21,26,27].
The advantages of robotic surgery are more valuable
when operating in the confined area, as in the esopha-
geal surgery. The dexterity and articulated instruments
permit seven degrees of motion including in/out; rota-
tion; pitch at wrist; yaw at wrist; pitch at fulcrum; yaw at
fulcrum and grip strength [20]. The improved tremor
free motion stability can add to fine movements and fa-
cilitate a precise dissection and suturing in a confinedoperating space. As a result, we enjoyed atraumatic dis-
section during the mediastinal dissection of the esopha-
gus and surrounding lymph nodes. Additionally, we did
not encounter any iatrogenic trauma during the proced-
ure and achieved advantages in operative time and blood
loss.
In comparison to previously reported studies, our
study showed reduced total operating time. The total
operating time of the procedure in our series was
204.94 mins. The first performed robotic-assisted esopha-
gectomy in 2003 reported total operative time of 246 mins
[28]. Subsequent case series by van Hillgers et al. reported
total operative time of 450 (range 370–550) min and thor-
acoscopic time of 180 (range 120–240) mins from experi-
ence in 21 patients [9]. Boone et al. reported median
operative time of 450 mins in a series of 47 patients [27].
Some of the transhiatal approached had reported total op-
erative time of 267.71 mins [22] and 311 mins [23]. In the
report from Sarkaria et al. the median total operative time
was 556 min (range 395–807) [24]. The relatively low total
operative time in our series was a result of increased ex-
perience in robotic surgery, a well focused operating team
as well as nursing staff ’s familiarity with the procedures
and equipments. We were able to reduce the docking time
from 30 mins in initial days to 5 mins in the most recent
case. This significant decrease represents the learning
curve of the surgeon and team. The estimated blood
loss was 86.75 ml in our study. Other publications have
reported blood loss ranging from 40–625 ml using
similar approach [9,21,27]. Papers focused on the trans-
hiatal approach reported blood loss of 54 ml [22] and
97.2 ml [23]. None of our patient required blood trans-
fusion. This is of clinical significance as various studies
have indicated that esophageal cancer patients with
major blood loss receiving blood transfusions have a
worse prognosis [29,30].
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1.2 days and 8 days, respectively. Other studies have re-
ported ICU stay ranging from 1.8 day to 4 days [9,22,27]
and hospital stay ranging from 8.7 days to 18 days
[9,22-24,27]. Weksler B et al. compared the robotic
esophagectomy with the traditional MIE and found no
significant differences in operative time, blood loss,
number of resected lymph nodes, length of ICU/hospital
stay and postoperative complications [31].
In our study, we did not encounter any in-hospital
mortality. Approximately, 80% of the patient population
was alive at the median follow up of 10 months. There
were no treatment related deaths. Two patients had re-
currence of the cancer, one of which died while other
was disease free following the further treatment. The
complication rate was low in our study with reported
complications in only 19.28% of the study population. In
general, the transthoracic approach is more aggressive
than the transhiatal approach and is more likely to cause
cardiopulmonary complications, anastomotic and chyl-
ous leaks, vocal cord paralysis, and wound infection
[32]. However, a study by Satoh et al. has showed signifi-
cantly reduced incidence of recurrent nerve palsy by
robotic thoracoscopic esophagectomy in comparison to
conventional thoracoscopic esophagectomy [33]. Al-
though, we encountered only two cases with recurrent
nerve palsy, we advocate extreme caution during the en-
bloc resection as there are chances of damaging recur-
rent nerve and its small branches that are located in the
fatty tissue of the superior mediastinum. In our series,
the post-operating complications reduced markedly in
due course, with reported 3 cases anastomotic leak from
first 32 cases in our previous publication [11] and no
further incidences from last 51 cases. Similarly, there
were no further cases of chyle leak from our last
51 cases.
A prospective randomized clinical trial is underway for
comparing robot-assisted thoraco-laparoscopic esopha-
gectomy with the open transthoracic esophagectomy
[34]. We are really hopeful that the trial will furnish the
similar results to our study for robotic esophagectomy.
If the trial hypothesis is proved, robot esophagectomy
can be considered as treatment option related with a
lower postoperative complications, lower blood loss and
shorter hospital stay with at least similar oncologic out-
comes and better postoperative quality of life [34].
The major drawback of the robotic system is the lack
of haptic sensations. This limitation is mainly significant
in procedures where touch is an important component.
However, the recent surgical innovations are focused on
the development of systems that transmits the haptic
feedback to surgeon [35]. As the surgeon works alone at
a console, learning procedures and training to others
can be sometimes challenging [20]. Finally, the cost ofthe equipments could be additional limitation. However,
robot- assisted surgery has already confirmed cost sav-
ings from minimal blood loss, morbidity and reduced
hospital stay [8].
Conclusion
We found robot-assisted thoracoscopic esophagectomy
acceptable for treatment of esophageal cancer. The pro-
cedure allowed precise en-bloc dissection with lymphad-
enectomy in mediastinum. The advantages of robotic
system helped us to minimize operative time, blood loss
and complications. We are optimistic that future ran-
domized trials will establish this procedure as standard
of care for esophageal cancer.
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